Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis, Inc. (NASDAQ: PSNL) announced the launch of NeXT Personal, a next-generation tumor-informed liquid biopsy assay that enhances detection of molecular residual disease (MRD) with a sensitivity down to 1 part-per-million. This marks a 10- to 100-fold improvement over existing technologies, enabling earlier detection across various cancers, including challenging low mutational burden and early-stage cancers. NeXT Personal creates a tailored liquid biopsy panel from a patient’s tumor to better monitor cancer treatment.
Personalis, Inc. (NASDAQ: PSNL) announced participation in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021. This event showcases Personalis' leadership in advanced cancer genomics aimed at precision cancer therapies. Interested parties can access a pre-recorded webcast of the presentation for 90 days through their website. Personalis’ NeXT Platform® supports comprehensive genomic insights from tissue samples, enhancing diagnostics for biopharmaceutical customers. For further details, visit investors.personalis.com.
Personalis, a leader in advanced cancer genomics, will participate in the Society for Immunotherapy of Cancer Annual Meeting from November 12-14. The company will present online exhibits, including the Personalis NeXT Platform for comprehensive tumor and immune microenvironment analysis. Key presentations include research on liquid biopsies and therapeutic resistance in various cancers. An industry symposium titled 'Leveraging comprehensive genomic data for diagnostic capabilities' will also be featured on November 12.
Personalis, Inc. (Nasdaq: PSNL) reported a 12% increase in third-quarter revenue, totaling $22.3 million compared to $19.8 million in 2020. The company achieved record revenue of $8.6 million from biopharma clients, a 50% growth. New orders for cancer genomic testing exceeded quarterly revenue by three times. Notably, Personalis secured a $10 million contract with the VA Million Veteran Program. Despite these gains, the net loss rose to $17.7 million, worsening from a $9.5 million loss in the previous year. The fourth quarter outlook anticipates revenue between $20.2 million and $20.4 million.
Personalis, Inc. (NASDAQ: PSNL) has expanded its NeXT Platform, enhancing its ability to analyze tumor-immune interactions crucial for cancer therapy responses. Key new features include InfiltrateID™, which identifies immune cell populations; RepertoireID™, which characterizes B-cell receptors; and SHERPA™, an advanced neoantigen prediction algorithm. These improvements aim to facilitate better patient stratification in cancer treatments. Personalis continues to be a leader in advanced genomics, operating a significant sequencing operation and focusing on comprehensive genomic tumor profiling.
Personalis, Inc. (NASDAQ: PSNL) announced the issuance of two significant US patents on October 12 and 26, 2021, related to its NeXT Liquid Biopsy platform. The first patent, US Patent No. 11,142,802, focuses on methods for identifying cancer mutations in cell-free nucleic acids, especially beneficial for early-stage cancer patients. The second patent, US Patent No. 11,155,867, details a deep sequencing method for analyzing exomes from cell-free samples. Combined, these patents enhance Personalis' intellectual property portfolio, supporting advancements in cancer detection and treatment.
Personalis, Inc. (Nasdaq: PSNL) announced the publication of its study on the SHERPA™ algorithm, significantly improving MHC-peptide binding prediction for neoantigen discovery. This new machine learning tool demonstrates a 1.44-fold increase in positive predictive value over existing tools, trained on a dataset of 2.15 million peptides across 167 HLA alleles. The study emphasizes SHERPA's potential in enhancing cancer therapy prediction and accelerating the development of personalized treatments, leveraging data from diverse cell lines.
Personalis, Inc. (NASDAQ: PSNL) will announce its third quarter 2021 financial results on November 4, 2021, before the market opens. The company will host a conference call at 5:30 a.m. PT to discuss its financials and recent developments. Interested parties can join via telephone or access a live webinar through the company’s investor website. Personalis specializes in advanced cancer genomics, providing insights from approximately 20,000 human genes, which facilitates precision cancer therapies and diagnostics.
Personalis, Inc. (NASDAQ: PSNL) has appointed Robert Bruce as Vice President of Reimbursement. With over 25 years of experience in reimbursement strategies within clinical molecular diagnostics, Bruce aims to enhance access to advanced molecular diagnostic tests for cancer. Prior to joining Personalis, he held leadership roles at Clinical Genomics and other companies. His expertise is expected to facilitate growth in clinical laboratory testing at Personalis, enabling innovative solutions for understanding cancer at a molecular level.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
